A detailed history of Grandfield & Dodd, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Grandfield & Dodd, LLC holds 103,999 shares of EXAS stock, worth $5.15 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares
103,999
Previous 79,896 30.17%
Holding current value
$5.15 Million
Previous $3.38 Million 109.81%
% of portfolio
0.45%
Previous 0.23%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$42.43 - $70.83 $1.02 Million - $1.71 Million
24,103 Added 30.17%
103,999 $7.08 Million
Q2 2024

Aug 09, 2024

BUY
$41.33 - $74.26 $1.02 Million - $1.83 Million
24,672 Added 44.68%
79,896 $3.38 Million
Q1 2024

May 03, 2024

BUY
$56.27 - $73.77 $1.83 Million - $2.39 Million
32,453 Added 142.52%
55,224 $3.81 Million
Q4 2023

Jan 31, 2024

BUY
$59.06 - $75.72 $1.34 Million - $1.72 Million
22,771 New
22,771 $1.68 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $8.77B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Grandfield & Dodd, LLC Portfolio

Follow Grandfield & Dodd, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grandfield & Dodd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grandfield & Dodd, LLC with notifications on news.